Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America
Daxor shared new research showing its heart-measurement tool works well. When a company proves its technology helps sick patients, that builds trust in the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.